A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus

Trial Profile

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Livoletide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Alize Pharma; Millendo Therapeutics SAS
  • Most Recent Events

    • 20 Dec 2017 According to an Alize Pharma media release, Alize Pharma SAS was acquired by Millendo Therapeutics and subsequently changed its named to Millendo Therapeutics SAS.
    • 29 Oct 2015 Results published in an Alize Pharma media release.
    • 29 Oct 2015 Status changed from active, no longer recruiting to completed according to an Alize Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top